NCT00936858View on ClinicalTrials.gov

RAD001 for Patients With Radioiodine Refractory Thyroid Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

February 27, 2020

Study Completion Date

February 27, 2020

Conditions
Thyroid Cancer
Interventions
DRUG

RAD001

Trial Locations (4)

10029

Mt. Sinai Medical Center, New York

77030

MD Anderson Cancer Center, Houston

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

collaborator

M.D. Anderson Cancer Center

OTHER

collaborator

MOUNT SINAI HOSPITAL

OTHER

collaborator

Novartis

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT00936858 - RAD001 for Patients With Radioiodine Refractory Thyroid Cancer | Biotech Hunter | Biotech Hunter